As illustrated in Fig. 7, our findings reveal the novel function of NOX4 in reprogramming aerobic glycolysis initiated by activated Kras and inactivated p16 in PDAC, indicating its potential as a therapeutic target for PDAC and other cancers. This evidence concerns the gene CDKN2A and cancer.